Federal Court Overseeing Hundreds of Lipitor Lawsuits Prepares to Convene June Status Conference
New York, New York (PRWEB) June 06, 2015 -- Thousands of federally-filed Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that have been consolidated in a multidistrict litigation underway in U.S. District Court, District of South Carolina, continue to move forward. According to court documents, the proceeding is scheduled to convene its monthly status conference on Thursday, June 25, 2015 at 10:00 a.m. In preparation for the conference, the parties have been directed to submit a Joint Status Report to the Court no later than June 18, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is representing federal Lipitor lawsuit plaintiffs, and we expect that this conference will provide important information regarding the status of discovery and other matters relevant to those claims. We look forward to providing our clients with updates regarding the progress of this proceeding,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to provide free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Litigation
Lipitor is a statin medication that is intended to be used in conjunction with diet and exercise to lower LDL ("bad") cholesterol and triglycerides in the blood. According to court documents, the products liability litigation surrounding Lipitor has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) required all statin manufacturers to update their product labels with information regarding the medication’s potential to effect blood glucose levels. The FDA’s mandate was prompted by a study published the previous month in JAMA: Internal Medicine suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes.*
Court records indicate that more than 2,100 Lipitor lawsuits are now pending in the federal multidistrict litigation underway in South Carolina, all of which were filed on behalf of individuals who allegedly developed Type 2 diabetes related to their use of the statin medication. Plaintiffs accuse Pfizer, Inc. of concealing knowledge of this potential risk in order to protect profits it derived from the sale of Lipitor. They also assert that the label modifications the company made in response to the FDA’s 2012 order were not adequate to warn patients about the association between Lipitor and diabetes.
Lipitor patients who allegedly developed Type 2 diabetes due to their use of the statin medication may be entitled to compensation. To learn more about the federal Lipitor litigation, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Sandy A. Liebhard, Lipitor Lawsuit Diabetes Information Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article